As Canada moves closer towards legalization of cannabis, the country’s government has released the restrictions it plans to impose on companies planning to differentiate their products through branding strategies.
On Monday (March 19) the Canadian federal government released a report on the discussion it held with interested parties in the cannabis industry.
In the report, among a variety of topics, came the proposals on the plain packaging presented for actual marijuana products.
The intended proposal is that… the regulations would set strict requirements related to the use of branding, logos, and colours,” the report said.
“We are taking a public health approach to legalizing and regulating cannabis, and we are committed to keeping cannabis out of the hands of children and youth,” Minister of Health Ginette Petitpas Taylor said in a statement.
“Measures such as the packaging and labelling requirements announced today will help to achieve this goal.”
— Bryan Mc Govern (@McGbryan) March 19, 2018
Cannabis industry responds: “The packaging requirements proposed today will work against that goal”
Allan Rewak, acting executive director of Cannabis Canada Association said in a statement it will be vital for LPs to be allowed to differentiate their products to adult consumers. The Cannabis Canada Association is an organization for Canadian LPs.
“The packaging requirements proposed today will work against that goal,” Rewak said on Monday.
The association said the restrictions on companies’ branding and logos would “hinder” the legal industry and its development in Canada.
Jay Wilgar, CEO of Newstrike Resources (TSXV:HIP) which is a company that has focused a lot of its business into branding, told INN in a statement he understands these proposed regulations were drafted to combat the black market.
“We also think that in order to effectively transition away from the black market, LPs need to be able to educate consumers as to why their products are better and safer,” Wilgar said.
MedReleaf issued its own statement calling out the government’s proposals for failing to see the differences between cannabis and tobacco since the restrictions on marijuana are similar to those of cigarettes.
“We’re fearful that the proposed rules shared today will leave many consumers confused and as a result they may turn to what they know, which is the black market,” Neil Closner, board chair for the association and CEO of MedReleaf (TSX:LEAF) said.
MedReleaf said its preferred approach would be on similar to alcohol in which consumers can “distinguish between brands… including product types, qualities, varieties, effects, sources of origin and awards garnered.”
The company unveiled its first lifestyle brand in February, meant to appeal recreational consumers of marijuana.
In an email statement to INN, Trent Kitsch, president of HIKU Brands (CSE:HIKU), another company with a focus on cannabis brands, said he thinks the packaging proposals could have been “less restrictive” but he views this as another milestone toward legalization.
“We shouldn’t be treating cannabis as harmful on par with things like tobacco,” Kitsch said. “Ultimately the government has the balance of power on this decision.”
Branding is the future of the cannabis market
Experts agree on branding raising as a metric for investors to focus on as they make picks on which stocks to invest in.
“I don’t think investors are currently looking to see who is going to be the biggest [or] who is going to grow the most. I think they are looking at it now as a retailing business,” Steven Feldman, a cannabis investor, co-founder, and director of Liberty Leaf Holdings (CSE:LIB) told INN.
A February research note from Eight Capital analyst Daniel Pearlstein asked investors to start thinking differently about cannabis. Pearlstein said consumers will make decisions in this industry according to the brands available.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Editorial Disclosure: HIKU Brands is a client of the Investing News Network. This article is not paid-for content.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.